Analyst Ram Selvaraju of H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals, with a price target of $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Hold rating due to a combination of factors influencing Inovio Pharmaceuticals’ current and future prospects. One key consideration is the company’s financial performance, as Inovio reported a net loss of $23.5 million in the second quarter of 2025, which was slightly better than expected. Additionally, the company is progressing with the Biologics License Application (BLA) for INO-3107, aiming for FDA acceptance by the end of 2025, with potential regulatory approval around mid-2026 if priority review is granted. However, a competing treatment for recurrent respiratory papillomatosis (RRP) has a PDUFA date set for August 2025, which could impact INO-3107’s market entry and competitiveness.
Another factor contributing to the Hold rating is the company’s cash position and funding needs. As of June 2025, Inovio had $47.5 million in cash and investments, with a pro forma cash position of approximately $70 million after a public offering. This is expected to fund operations into the second quarter of 2026, but the company may need to raise additional capital within the next 12 months. Additionally, while long-term efficacy data for INO-3107 in RRP patients is promising, with significant clinical benefits and no serious adverse events, the financial and competitive landscape suggests a cautious approach, warranting a Hold rating at this time.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.50 price target.